Base4 and Hitachi High-Tech Collaborate on Developing Novel Nanopore DNA-Sequencing System
The core DNA-sequencing technology is based on the concept of passing a single strand of DNA through a nanometer-scale pore and reading out the sequence directly as it does so.
Base4 Innovation Ltd., a Cambridge-based DNA-sequencing company, and Hitachi High-Technologies Corporation, a technology company developing and manufacturing scientific and medical systems, announced that they have entered into an agreement to develop a long read-length, single-molecule, nanopore-based DNA-sequencing system based on Base4’s technology and Hitachi’s state-of-the-art instrumentation.
The core DNA-sequencing technology is based on the concept of passing a single strand of DNA through a nanometer-scale pore and reading out the sequence directly as it does so. A method was developed by Base4 to increase the signal from the single molecule as it passes through the pore by using laser light enhanced by gold structures. Minimal sample preparation is required and the signal can be read from unlabelled DNA.
The system offers easy analysis of genetic material. It will be able to directly read DNA modifications, such as methylation, which is relevant to the genes associated with cancer, as well as achieve long read lengths.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
